More Analysts on Wall Street are Starting to Believe Dexcom ' s Stock is Now Fully Valued

So, on August 18, 2021, the crowd-sourced content service for financial markets known as SeekingAlpha.com, which often contains archived investor presentations and earnings transcripts from publicly-held companies, issued not one but TWO (2) slight warnings about Dexcom stock. Links to those two articles are listed below:https://seekingalpha.com/article/4450293-dexcom-too-expensive-considering-the-prospects AND https://seekingalpha.com/article/4450338-dexcom-future-sales-moderate-expectations Dexcom was the first mover into the market for continuous glucose monitors (CGMs), at least in the U.S. But Dexcom is hardly the only company operating in the CGM space. Dexcom has also delivered rapid growth, increasing revenue by 43% in 2019.So far, investors have done well investing in Dexcom. Its stock price has increased by 459% over the last 5 years.  Also over the past 5 years, Dexcom ' s revenue has grown by an average of 37.5%, and at the end of 2019, the company earned a net profit for the first time. Dexcom management expects the company to grow at a CAGR of 15-20% until 2025 inclusive, and the EBITDA margin target is 30%. But the rate of revenue growth is starting to slow down, so the consensus is that Dexcom management ' s expectations do not appear very conservative and might be a little on the bullish side. In the opinion of a growing number of analysts, the current targets in terms of financial indicators for Dexcom is too low concerning the company ' ...
Source: Scott's Web Log - Category: Endocrinology Tags: Abbott ADA Scientific Sessions CGM Dexcom GCMS Libre sensor Type 1 Type 2 Source Type: blogs